ENDRA Life Sciences (NASDAQ:NDRA) Stock Price Breaks Below 200 Day Moving Average – Here’s What Happened

Shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $4.81 and traded as low as $4.70. ENDRA Life Sciences shares last traded at $4.7750, with a volume of 1,200 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, ENDRA Life Sciences currently has a consensus rating of “Hold” and an average price target of $25.00.

ENDRA Life Sciences Trading Down 4.7%

The company has a market cap of $7.16 million, a PE ratio of -0.75 and a beta of -0.07. The business’s 50-day simple moving average is $5.43 and its 200-day simple moving average is $4.81.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.21. On average, research analysts predict that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI purchased a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned approximately 2.24% of ENDRA Life Sciences at the end of the most recent quarter. 1.19% of the stock is owned by hedge funds and other institutional investors.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic tools for tissue characterization. The company’s lead technology is Thermo-Acoustic Enhanced Ultrasound (TAEUS), which is designed to enhance conventional ultrasound systems with additional information about tissue properties.

ENDRA is initially applying TAEUS to the assessment of liver disease, including the detection and measurement of liver fat associated with conditions such as nonalcoholic fatty liver disease.